US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its share plunge after it revealed that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration regarding the New Drug Application (NDA) for Vyondys 53 (golodirsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.
The decision comes as something of a surprise, given that golodirsen is similar to Sarepta's already marketed drug Exondys 51 (eteplirsen), which was approved by the agency for use in another subset of Duchenne patients in September 2016.
The company’s shares fell nearly 4% by close of regular trading and slumped a further 13.3% to $104.31 after hours. Sarepta said it will immediately request a meeting with the FDA to determine next steps.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze